A recently discovered target with high potential for theranostic applications in glioma and brain metastases is prostate specific membrane antigen (PSMA); a transmembrane protein that is already successfully exploited for the treatment of prostate cancer patients [2]. The gene discussed is FOLH1; the disease is central nervous system cancer.